Mingxi Li
Partner @ GT Healthcare Capital Partners
Jingan, China
Mingxi Li is a funding round investor at GT Healthcare Capital Partners in Jingan focused on Health Care and Therapeutics. Dr. MingXi Li serves as Partner at GT Healthcare Capital Partners. Experienced with identifying innovative technologies and commercializing them, MingXi is a US trained professional focusing on life science sector with keen understanding of global and China healthcare market.He has established a track record of investing in China as well ascross-border transactions, and stayed well connected with industrial leaders, entrepreneurs, investors and academia in both China and US.MingXi serves on the board of a number of prominent pharmaceutical and diagnostic companies in China as well. He was Senior Director at Simcere Pharmaceutical Group from 2013 to 2017, and managed Simcere’s portfolio of investments (>150M USD) in various venture funds, including Cormorant Asset Management (MA, USA), Ally Bridge Group (HK), Partners Innovation Fund (MA, USA), PointGuard Ventures (CA, USA), Bohe Angels (Suzhou, China) and Tenyall Capital (Nanjing, China). He also served on the investment committee of Tenyall Capital.MingXi graduated with a B.S. in Biological Science and Biotechnology from Tsinghua University and has a Ph.D. in Biochemistry from University of Illinois at Urbana-Champaign.Earlier in his career, he worked in Jiuding Capital, covering Chinese pharma/IVD/hospital sectors, and later at Simcere Pharma/Bioscikin covering clinical and pre-clinical stage biopharma investments globally.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Mingxi Li invests in
Stages Mingxi Li invests in
Countries Mingxi Li invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (100%)
- Therapeutics 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process. | $27M / Jun 11, 2019 |
GT Healthcare Capital Partners (“GT Healthcare”) is an Asia-based private investment partnership that specializes in healthcare investments around the globe that aim to change technology landscapes. GT Healthcare intends to provide capital and scale expertise to healthcare businesses in Asia / Greater China.
GT Healthcare Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alan Au
Founder / Managing Partner
|
|||
Jai Hyun Kwon
Venture Partner
|
|||
|
Jason Yeung
Partner
|
|||
|
Mingxi Li
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Mingxi Li invest in?
Mingxi Li invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mingxi Li?
Public channels for Mingxi Li include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Mingxi Li last invest?
The most recent investment recorded for Mingxi Li closed in Jun 2019. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
